Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The same MORF-057 molecule is being evaluated in a double-blind, Phase 2b placebo-controlled RCT (EMERALD-2, NCT05611671) with 282 participants meeting similar inclusion criteria but specifically requiring inadequate response to aminosalicylates, corticosteroids, immunosuppressants, or advanced UC therapies, measuring clinical remission using mMS at 12 weeks as primary endpoint
.png)
Mayo Clinic
Pharmacodynamics of drug-induced weight gain
Daniel Ghiyam, founder of MedPodLA and an active GLP-1 prescriber
Routine monitoring and follow-up should occur at regular intervals, typically every 3-4 months initially, then every 6 months once stable
US$ 25.18
US$ 25.60
US$ 29.04
US$ 23.77
US$ 20.63
US$ 22.49
US$ 21.96
US$ 20.08
